SCHEMBL7915822

SCHEMBL7915822

O=C(O)c1ccc2cccc(-c3c(F)cc(F)cc3F)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2D Q9UNK4 2/20 0.50
PTPN1 P18031 1/20 0.43
TTR P02766 4/20 0.42
HTR5A P47898 1/20 0.42
RORC P51449 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2C Q14957 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA6 P23280 1/20 0.39
CA9 Q16790 1/20 0.39
MAOA P21397 1/20 0.39
BLVRB P30043 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HCAR1 Q9BXC0 1/20 0.38
CSNK2A2 P19784 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7917826 0.92 PLA2G2D (0.46) PLA2G2DPTPN1TTRHTR5ARORC
SCHEMBL7918210 0.91 PLA2G2D (0.52) PLA2G2DPTPN1TTRRORCGRIN2D
SCHEMBL16502660 0.91 PLA2G2D (0.45) PLA2G2DPTPN1TTRHTR5ARORC
SCHEMBL16502647 0.90 PLA2G2D (0.49) PLA2G2DPTPN1TTRRORCGRIN2D
SCHEMBL16502500 0.90 PLA2G2D (0.49) PLA2G2DPTPN1TTRRORCGRIN2D
SCHEMBL16509453 0.87 PLA2G2D (0.42) PLA2G2DPTPN1TTRRORC
SCHEMBL16502499 0.87 LMNA (0.48) PLA2G2DTTRMEN1KMT2ACA12
SCHEMBL16502624 0.86 PLA2G2D (0.46) PLA2G2DPTPN1TTRRORCGRIN2D
SCHEMBL16502480 0.86 PLA2G2D (0.48) PLA2G2DPTPN1TTRHTR5ARORC
SCHEMBL16502551 0.85 KDM4E (0.49) PLA2G2DPTPN1TTRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A PLA2G2D 841/4885PTPN1 2674/4885TTR 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.